Philip Bejon/Malar J

Maintenance of high temporal Plasmodium falciparum genetic diversity and complexity of infection in asymptomatic and symptomatic infections in Kilifi, Kenya from 2007 to 2018.Kimenyi KM, Wamae K, Ngoi JM, de Laurent ZR, Ndwiga L, Osoti V, Obiero G, Abdi AI, Bejon P, Ochola-Oyier LI
Malar J, (2022). 21:192

Factors influencing health workers' compliance with outpatient malaria 'test and treat' guidelines during the plateauing performance phase in Kenya, 2014-2016.Amboko B, Stepniewska K, Machini B, Bejon P, Snow RW, Zurovac D
Malar J, (2022). 21:68

The Plasmodium falciparum Rh5 invasion protein complex reveals an excess of rare variant mutations.Ndwiga L, Osoti V, Ochwedo KO, Wamae K, Bejon P, Rayner JC, Githinji G, Ochola-Oyier LI
Malar J, (2021). 20:278

Spatial-temporal clustering of malaria using routinely collected health facility data on the Kenyan Coast.Kamau A, Mtanje G, Mataza C, Bejon P, Snow RW
Malar J, (2021). 20:227

Building momentum for malaria vaccine research and development: key considerations.Chitnis CE, Schellenberg D, Vekemans J, Asturias EJ, Bejon P, Collins KA, Crabb BS, Herrera S, Laufer M, Rabinovich NR, Roestenberg M, Shearley A, Tinto H, Wentworth M, O'Brien K, Alonso P
Malar J, (2020). 19:421

Trends in health workers' compliance with outpatient malaria case-management guidelines across malaria epidemiological zones in Kenya, 2010-2016.Amboko B, Stepniewska K, Macharia PM, Machini B, Bejon P, Snow RW, Zurovac D
Malar J, (2020). 19:406

Malaria infection, disease and mortality among children and adults on the coast of Kenya.Kamau A, Mtanje G, Mataza C, Mwambingu G, Mturi N, Mohammed S, Ong'ayo G, Nyutu G, Nyaguara A, Bejon P, Snow RW
Malar J, (2020). 19:210

Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial.Talisuna AO, Oburu A, Githinji S, Malinga J, Amboko B, Bejon P, Jones C, Snow RW, Zurovac D
Malar J, (2017). 16:46

Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population.Ochola-Oyier LI, Okombo J, Wagatua N, Ochieng J, Tetteh KK, Fegan G, Bejon P, Marsh K
Malar J, (2016). 15:261

Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast.Kangoye DT, Noor A, Midega J, Mwongeli J, Mkabili D, Mogeni P, Kerubo C, Akoo P, Mwangangi J, Drakeley C, Marsh K, Bejon P, Njuguna P
Malar J, (2016). 15:213

Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies.Hodgson SH, Douglas AD, Edwards NJ, Kimani D, Elias SC, Chang M, Daza G, Seilie AM, Magiri C, Muia A, Juma EA, Cole AO, Rampling TW, Anagnostou NA, Gilbert SC, Hoffman SL, Draper SJ, Bejon P, Ogutu B, Marsh K, Hill AV, Murphy SC
Malar J, (2015). 14:33

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.Vekemans J, Marsh K, Greenwood B, Leach A, Kabore W, Soulanoudjingar S, Asante KP, Ansong D, Evans J, Sacarlal J, Bejon P, Kamthunzi P, Salim N, Njuguna P, Hamel MJ, Otieno W, Gesase S, Schellenberg D
Malar J, (2011). 10:221

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A
Malar J, (2011). 10:222

What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K
Malar J, (2009). 8:242

Incorporating a quiz into informed consent processes: qualitative study of participants' reactions.Molyneux S, Gikonyo C, Marsh V, Bejon P
Malar J, (2007). 6:145